The total return over the past 12 months is -20.21% vs. +15.54% for the S&P 500. So far it's up -0.49% this year. Includes price appreciation + reinvested dividends.
| Category | 1Y (TTM) | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Price CAGR | (20.21%) | (18.94%) | (28.56%) | N/A | N/A | N/A |
| Total Return CAGR | (20.21%) | (18.94%) | (28.56%) | N/A | N/A | N/A |
| Revenue CAGR | (14.88%) | +3.22% | +45.50% | N/A | N/A | N/A |
| Net Income CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| EPS CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| Free Cash Flow CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| Operating Cash Flow CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| Dividends CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
Visualize historical growth rates over rolling horizons. Use the dropdown to select different metric vectors.
Recursion Pharmaceuticals, Inc. (RXRX)
| Year | Start price | End price | RXRX Return | SPY Return | Outperformance |
|---|---|---|---|---|---|
| 2026(YTD) | $4.09 | $4.07 | (0.49%) | +12.91% | (13.40%) |
| 2025 | $6.76 | $4.09 | (39.50%) | +17.72% | (57.22%) |
| 2024 | $9.86 | $6.76 | (31.44%) | +24.89% | (56.33%) |
| 2023 | $7.71 | $9.86 | +27.89% | +26.19% | +1.70% |
| 2022 | $17.13 | $7.71 | (54.99%) | (18.17%) | (36.82%) |
Start and end prices are split-adjusted closing prices. Total return includes reinvested dividends, so it can differ from the price change.
